
In this lesson on P2Y12 inhibitors (ADP inhibitors), you’ll learn the high-yield, test-relevant concepts behind the most common antiplatelet drugs used in cardiovascular care. In this lecture from This is Why, Dr. Busti will break down how platelet aggregation inhibitors work, when they’re used clinically, and the key differences between clopidogrel (Plavix), prasugrel (Effient), ticagrelor (Brilinta), and cangrelor (Kengreal)—so you can apply the “why” behind therapy (not just memorize drug names).
You’ll learn how to:
- The P2Y12 (ADP) receptor and how blocking it reduces platelet activation
- Where P2Y12 inhibitors fit in dual antiplatelet therapy (DAPT)
- High-yield uses: acute coronary syndrome (ACS), PCI/stents, and secondary prevention
- Major adverse effects (including bleeding) and top safety pearls
- The exam-favorite comparisons: prodrug activation, onset/offset, reversibility, and IV vs PO options
The goal = make medical education easy and clinically relevant.
Chapter Table of Contents
00:00 - Introduction to P2Y12 Inhibitors
02:51 - Agents
04:03 - Indications & Uses
05:24 - Net Benefit
07:58 - Pharmacology
22:30 - Clinical Knowledge
41:35 - Summary
If this helped you, please like, subscribe to our YouTube Channel, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.
Don’t forget to turn on notifications on YouTube so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!
#p2y12inhibitors #clopidogrel #antiplateletpharmacology #ticagrelor #drbusti
Speaker:
Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, is a licensed healthcare professional and medical educator with over 30 years of experience in clinical practice and academic teaching. He has trained and practiced as a nurse, pharmacist, and physician, bringing a uniquely comprehensive perspective to patient care and medical education.
Dr. Busti is dedicated to advancing evidence-based medicine and helping clinicians understand the underlying “why” behind clinical decisions to improve patient outcomes.
About This Channel:
This content is created by Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, a board-certified physician with training at Johns Hopkins School of Medicine and University of Oxford and a medical educator for healthcare professionals and students. All material is based on current medical literature and evidence-based guidelines that align with principles of evidence-based medicine (EBM) and Evidence-Based Healthcare (EBHC).
Disclaimer:
This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

P2Y12 Inhibitors (ADP Inhibitors): Antiplatelet Pharmacology Made Easy
P2Y12 Inhibitors (ADP Inhibitors): Antiplatelet Pharmacology Made Easy